53 terminated. 53 Phase 3, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 53 | Terminated 53 |
| Phase 2 | 8 | Terminated 8 |
Follow Schizophrenia: new trials by email Literature Review of Schizophrenia trials Research Report on Schizophrenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure Clozapine, Esketamine Nasal Product, Escitalopram - Schizophrenia and Related Disorders, Major Depressive Disorder | Phase 3 | Terminated | Dr. Inge Winter | 1 | 2025-04-27 | 2026-11-05 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia Valbenazine, Placebo - Schizophrenia | Phase 3 | Terminated | Neurocrine Biosciences | 8 | 2023-01-05 | 2024-11-12 |
| An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia Xanomeline and Trospium Chloride Capsules - Schizophrenia | Phase 3 | Terminated | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 4 | 2022-11-08 | 2024-06-12 |
| Study to Assess Adverse Events and Change in Disease Activity of Oral Cariprazine Capsules in Adult Participants With Schizophrenia Cariprazine, Placebo - Schizophrenia | Phase 3 | Terminated | AbbVie | 34 | 2022-08-18 | 2025-10-20 |
| A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan SEP-363856 - Schizophrenia | Phase 3 | Terminated | Sumitomo Pharma Co., Ltd. | 68 | 2022-05-16 | 2025-03-19 |
| A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study Iclepertin - Schizophrenia | Phase 3 | Terminated | Boehringer Ingelheim | 1356 | 2022-03-21 | 2026-04-08 |
| A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase SEP-363856 50 mg, SEP-363856 75 mg, Placebo - Schizophrenia | Phase 2 / Phase 3 | Terminated | Sumitomo Pharma Co., Ltd. | 83 | 2021-03-29 | 2024-03-15 |
| A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia SEP-363856 - Schizophrenia | Phase 3 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 463 | 2019-11-20 | 2024-12-16 |
| A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite® Abilify MyCite® - Schizophrenia | Phase 3 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 277 | 2019-04-29 | 2021-09-05 |
| Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia Placebo, AVP-786 - Schizophrenia | Phase 2 / Phase 3 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 136 | 2019-02-15 | 2026-09-29 |
| Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia WSE, Placebo Oral Tablet - Schizophrenia | Phase 2 / Phase 3 | Terminated | Chengappa, K.N. Roy, MD | 47 | 2018-12-01 | 2024-10-08 |
| Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia Cariprazine, Placebo - Schizophrenia | Phase 3 | Terminated | AbbVie | 587 | 2018-07-30 | 2022-04-11 |
| Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia Lu AF35700, Risperidone, Olanzapine - Treatment-resistant Schizophrenia | Phase 3 | Terminated | H. Lundbeck A/S | 119 | 2017-07-20 | 2020-01-21 |
| Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults NaBen®, Placebo - Schizophrenia | Phase 2 / Phase 3 | Terminated | SyneuRx International (Taiwan) Corp | 280 | 2017-03-29 | 2024-05-24 |
| Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia Pimavanserin - Schizophrenia | Phase 3 | Terminated | ACADIA Pharmaceuticals Inc. | 995 | 2017-01-01 | 2025-08-24 |
| "Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients" N-Acetylcysteine, Placebo, IPPI (Integrated Preventive Psychological Intervention) - Prodromal Schizophrenia | Phase 3 | Terminated | University Hospital, Bonn | 48 | 2016-09-01 | 2022-05-09 |
| Pharmacovigilance in Gerontopsychiatric Patients Phenobarbital, Phenytoin, Carbamazepine - Dementia, Depression | Phase 3 | Terminated | Hannover Medical School | 407 | 2015-01-01 | 2018-02-28 |
| Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen® NaBen®, Placebo - Schizophrenia | Phase 2 / Phase 3 | Terminated | SyneuRx International (Taiwan) Corp | 60 | 2014-06-01 | 2024-05-09 |
| SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg), Placebo - Schizophrenia | Phase 3 | Terminated | Shire | 1 | 2013-02-01 | 2021-06-22 |
| Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia SPD489 - Schizophrenia | Phase 3 | Terminated | Shire | 2 | 2013-02-01 | 2021-06-22 |
Showing 20 of 53. Sign in to see all of them.
Psychotic Disorders (7) · Bipolar Disorder (3) · Cognitive Dysfunction (2) · Metabolic Syndrome (2) · Anxiety Disorders (1) · Body Weight Changes (1) · Dementia (1) · Depression (1) · Depressive Disorder, Major (1) · Empowerment (1) · Mania (1) · Marijuana Abuse (1) · Medication Adherence (1) · Psychophysiologic Disorders (1)
Mental Disorders (53) · Schizophrenia Spectrum and Other Psychotic Disorders (53) · Pathological Conditions, Signs and Symptoms (5) · Signs and Symptoms (4) · Bipolar and Related Disorders (3) · Mood Disorders (3) · Neurocognitive Disorders (3) · Behavior (2) · Body Weight (2) · Cognition Disorders (2) · Glucose Metabolism Disorders (2) · Hyperinsulinism (2) · Insulin Resistance (2) · Metabolic Diseases (2) · Nervous System Diseases (2)
Quetiapine Fumarate (11) · Aripiprazole (8) · Risperidone (8) · bifeprunox (6) · ziprasidone (6) · LY 2140023 (4) · Olanzapine (4) · Lisdexamfetamine Dimesylate (3) · Memantine (3) · SEP-363856 (3) · Bupropion (2) · Clozapine (2) · Escitalopram (2) · Lithium (2) · Sertraline (2)
Otsuka Pharmaceutical Development & Commercialization, Inc. (7) · AstraZeneca (4) · Denovo Biopharma LLC (4) · H. Lundbeck A/S (4) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (4) · Shire (3) · AbbVie (2) · Hannover Medical School (2) · M. Schaefer, MD (2) · Sumitomo Pharma Co., Ltd. (2) · SyneuRx International (Taiwan) Corp (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · ACADIA Pharmaceuticals Inc. (1) · Augusta University (1) · BioLineRx, Ltd. (1)
United States (30) · Ukraine (11) · Bulgaria (9) · Germany (9) · Russia (9) · Poland (8) · Taiwan (8) · Romania (7) · Japan (6) · Malaysia (6) · Puerto Rico (6) · Canada (5) · Croatia (5) · India (5) · Serbia (5)
Martin Schaefer, MD (2) · Anantha Shekhar, MD, PhD (1) · Arnon Aharon, MD (1) · Birgit Ekholm, MD (1)
PMID 24111983, PMID 31390660, PMID 32840872, PMID 17474812, PMID 18447935, PMID 23898805, PMID 24772351, PMID 25890643, PMID 28088223, PMID 35421287, PMID 36369028, PMID 38085556, PMID 41401709
2005 (1), 2016 (1), 2017 (1), 2019 (1)